• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Intensive Systolic BP Target Cost-Effective for Patients at High Cardiovascular Risk

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 19, 2025.

TUESDAY, Aug. 19, 2025 -- For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood pressure (SBP) target (<120 mm Hg) seems cost-effective at most settings with measurement error, according to a study published online Aug. 19 in the Annals of Internal Medicine.

Karen C. Smith, Ph.D., from Brigham and Women's Hospital in Boston, and colleagues used data from the National Health and Nutrition Examination Survey to generate a simulated cohort of adults at high cardiovascular risk who met Systolic Blood Pressure Intervention Trial inclusion criteria and examined the effect of measurement error on the cost-effectiveness of intensive SBP targets. Incremental cost-effectiveness ratios (ICERs) were compared for SBP targets of less than 120, 130, and 140 mm Hg.

The researchers found that the ICER for the target of less than 120 versus less than 130 mm Hg was $24,400 per quality-adjusted life-year (QALY) with research-grade SBP measurement (mean error, 0 mm Hg) in the base-case analysis. The ICER increased to $42,000 per QALY with average measurement error (mean error, 7.3 mm Hg in the <120-mm Hg target). In sensitivity analyses, in scenarios with high error (mean error ≥14.6 mm Hg in the <120-mm Hg target), the ICER for the target of less than 120 mm Hg was greater than $100,000 per QALY, when an inflection point for increasing risk for cardiovascular disease was at or above 116 mm Hg and in scenarios with a medication-taking disutility of at least 0.003 per antihypertensive medication.

"This study should give patients at high cardiovascular risk and their clinicians more confidence in pursuing an intensive blood pressure goal," Smith said in a statement. "Our findings suggest the intensive <120 mm Hg target prevents more cardiovascular events and provides good value, and this holds true even when measurements aren't perfect."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.